U.S. extends shelf-life of AstraZeneca's COVID-19 antibody cocktail to 24 months
jetcityimage/iStock Editorial via Getty Images         

A U.S. health department body and the U.S. Food and Drug Administration (FDA) authorized an extension to the shelf-life of AstraZeneca's (NASDAQ:AZN) COVID-19 antibody-based cocktail Evusheld.
The shelf-life for specific lots of refrigerated Evusheld has been extended from 18 months to 24 months, the Assistant Secretary for Preparedness and Response and the FDA said in a statement on Tuesday.
Evusheld currently has an emergency use approval from the FDA.
The extension was granted following a "thorough review" of data submitted by AZN.
U.S.-listed shares of AZN earlier closedÂ slightly lowerÂ at $65.93.